Dexcom: Buy Rating Reaffirmed on Sustained Double-Digit Growth Outlook, Margin Expansion, and Governance Enhancements

William Blair analyst Steven Lichtman has maintained their bullish stance on DXCM stock, giving a Buy rating today.

Steven Lichtman has given his Buy rating due to a combination of factors that emerged from Dexcom’s 2026 investor day, where management reinforced a credible path to sustaining double‑digit revenue growth over the long term and outlined specific initiatives to broaden its addressable market through new product launches. He also views the company’s detailed margin expansion targets and the strong free‑cash‑flow profile, which underpins more aggressive near‑ and long‑term share repurchase plans, as supportive of shareholder value creation.

In addition, Lichtman highlights the strategic importance of Dexcom’s differentiated product pipeline, which he believes should help the company defend and extend its competitive position in continuous glucose monitoring. He further interprets the newly announced collaboration with Elliott Management, aimed at enhancing board oversight and governance, as a constructive step that can sharpen strategic focus and capital allocation, reinforcing his positive stance on the shares.

In another report released today, Wells Fargo also assigned a Buy rating to the stock with a $85.00 price target.